-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We keep our target of $278, 22.1x our 2027 EPS view, above JNJ's 10-year historical forward P/E average, justified by its improving growth outlook. We lift our 2026 EPS view to $11.66 from $11.63, mainly to reflect the Q1 beat. We keep our 2027 EPS at $12.58. JNJ delivered solid Q1 2026 results that were above expectations, with top-line sales growth of 9.9% Y/Y to $24.1B, demonstrating continued momentum across both the core Innovative Medicine (+11.2% Y/Y) and MedTech (+7.7% Y/Y) segments. The company reaffirmed its trajectory toward $101B in annual revenue for 2026 (CFRA: $101.3B) and expressed confidence in achieving double-digit growth by decade's end. We view this target as achievable driven by new product launches (Darzalex injectable, Icotyde, which is expected to be one of JNJ's largest products), an innovative pipeline, and key strategic initiatives (mid-2027 Orthopedics separation, which we think will unlock considerable value for JNJ and manufacturing expansions in North Carolina and Pennsylvania).